Skip to main content
. Author manuscript; available in PMC: 2018 Nov 6.
Published in final edited form as: Mol Pharm. 2017 Oct 3;14(11):4042–4051. doi: 10.1021/acs.molpharmaceut.7b00710

Figure 5. In vivo efficacy of HDL NPs as monotherapy and in combination with ibrutinib.

Figure 5

(a) SUDHL4 tumor xenografts were initiated in SCID-beige mice, and treated either 3 times or 5 times per week with 100µl of 1µM HDL NPs, injected via the tail vein. N=10 for each treatment group. *p<0.0001 vs. all other treatment groups by 1-way ANOVA; † p<0.0001 vs. PBS control only by 1-way ANOVA. (b) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 21. (c) TMD8 tumor xenografts were initiated in SCID-beige mice, and treated 5 times per week with PBS, 100µl of 1µM HDL NPs, 3mg/kg ibrutinib, or a combination of HDL NPs and ibrutinib for two weeks. N=10 for PBS, HDL NP alone, and ibrutinib alone. N=11 for HDL NP + ibrutinib. *p<0.05 v. all other treatment groups by 1-way ANOVA. (d) Waterfall plot of the change in tumor volume from Day 0 (start of treatment) to Day 14.